



Nanoparticles for Therapeutic and Diagnostic Applications

Collection Editor:

Prof. Dr. Wassana Yantasee

Department of Biomedical
Engineering, Oregon Health and
Science University, Portland, OR
97239, USA

Message from the Collection Editor

Nanoparticles have garnered intense interest as a therapeutic platform to treat a broad range of diseases, including cancer, metabolic, cardiovascular, skin, renal, inflammatory, and infectious disease. Well-designed nanoparticles can enhance the efficacy of traditional therapeutics through enhanced solubility, prolonged circulation or drug release, targeted delivery to disease sites, and reduced toxicity. Nanoparticles can be formulated for systemic, dermal, oral, and inhalation applications and optimized to overcome the delivery barriers of emerging therapeutics such as oligonucleotides, mRNA, and DNA with the potential to be safer than viral vector counterparts.

The Issue will focus on nanoparticle development and applications in broad ranges of diseases and delivery routes. Research toward increased understanding of pharmacokinetics, pharmacodynamics, toxicity, stability, and manufacturability of nanoparticles is also highly relevant.

We look forward to receiving your contributions to this Issue of *Bioengineering*.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical
Engineering, Texas A&M
University, College Station, TX
77843, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, Inspec, and other databases.

Journal Rank: JCR - Q2 (*Engineering, Biomedical*)

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 3.1 days (median values for papers published in this journal in the first half of 2024).

Contact Us

Bioengineering Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/bioengineering
bioengineering@mdpi.com
[X@Bioeng_MDPI](https://twitter.com/Bioeng_MDPI)